SCHEMBL30774512

SCHEMBL30774512

N#Cc1ccc(-c2cncc3c2OCCN3C(=O)C2CN(c3cccc(C#N)c3)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 5/20 0.45
▸ NOTUM Q6P988 1/20 0.45
▸ UCHL1 P09936 3/20 0.41
▸ DRD2 P14416 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ ROCK1 Q13464 1/20 0.35
▸ LRRK2 Q5S007 1/20 0.34
▸ SLC22A12 Q96S37 2/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ GRM5 P41594 1/20 0.33
▸ TNF P01375 1/20 0.33
▸ NOD1 Q9Y239 1/20 0.33
▸ GPR142 Q7Z601 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31635537 0.92 USP30 (0.43) USP30NOTUMUCHL1SLC22A12CYP11B1
SCHEMBL30774886 0.91 USP30 (0.45) USP30UCHL1SLC22A12CYP11B1CYP11B2
SCHEMBL30774432 0.87 USP30 (0.42) USP30UCHL1CYP11B2TNFNOD1
SCHEMBL30774840 0.85 ROCK2 (0.44) USP30UCHL1DRD2DRD3ROCK2
SCHEMBL30774578 0.85 USP30 (0.43) USP30UCHL1CYP11B1CYP11B2TNF
SCHEMBL30774882 0.81 USP30 (0.44) USP30UCHL1SLC22A12CYP11B1CYP11B2
SCHEMBL30774354 0.81 USP30 (0.43) USP30UCHL1SLC22A12
SCHEMBL31635534 0.81 USP30 (0.42) USP30UCHL1PAX8CYP11B1CYP11B2
SCHEMBL30774802 0.80 USP30 (0.42) USP30UCHL1PAX8CYP11B1CYP11B2
SCHEMBL30774590 0.80 USP30 (0.42) USP30UCHL1ROCK2ROCK1PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US claimed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP claimed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 USP30 728/4885NOTUM 517/4885UCHL1 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback